In this week’s Bulletin, we cover a recent study on the cost-effectiveness of MDMA-assisted therapy for PTSD, as well as a number of thinkpieces. As part of our 2021 Year in Review we identified trends that we’re watching in 2022. One of those was A Closer Eye on Insurance Coverage, where we identified the Global Initiative for Psychedelic Science Economics (GIPSE) as a key group to watch.


Previous articlePT298 – Michael Sapiro, PsyD – Vital Psychedelic Conversations
Next articlePT299 – Ed Prideaux – HPPD (Hallucinogen Persisting Perception Disorder): A Synopsis